VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.200
+0.002 (0.86%)
At close: Mar 9, 2026, 4:00 PM EDT
0.204
+0.004 (1.95%)
After-hours: Mar 9, 2026, 7:02 PM EDT
VolitionRx Revenue
VolitionRx had revenue of $627.28K in the quarter ending September 30, 2025, with 32.19% growth. This brings the company's revenue in the last twelve months to $1.47M, up 14.48% year-over-year. In the year 2024, VolitionRx had annual revenue of $1.23M with 59.10% growth.
Revenue (ttm)
$1.47M
Revenue Growth
+14.48%
P/S Ratio
18.67
Revenue / Employee
$19,627
Employees
75
Market Cap
27.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
| Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
| Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nortech Systems | 116.67M |
| TELA Bio | 77.06M |
| IRIDEX | 50.65M |
| Myomo | 41.64M |
| Spectral AI | 23.17M |
| NeuroOne Medical Technologies | 11.72M |
| Pulsenmore | 2.76M |
| Movano | 500.00K |
VNRX News
- 3 days ago - Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems - PRNewsWire
- 12 days ago - VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution - PRNewsWire
- 27 days ago - Volition Announces the Appointment of New Distributor for Nu.Q® Discover - PRNewsWire
- 4 weeks ago - VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - PRNewsWire
- 4 weeks ago - Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation - PRNewsWire
- 5 weeks ago - VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays - PRNewsWire
- 5 weeks ago - Volition Announces Data to Support Use of Nu.Q® NETs in New Indication - PRNewsWire
- 6 weeks ago - Volition Continues to Extend Access to Nu.Q® Vet Cancer Test - PRNewsWire